We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inha... Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. Show more
Represents Amnealโs fourth 505(b)(2) injectable approval in 2024 Ready-to-use oncology treatment used for multiple myeloma and mantle cell lymphoma Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX...
Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amnealโs injectables portfolio Amneal Pharmaceuticals, Inc. (Nasdaq:...
Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amnealโs injectables portfolio Amneal Pharmaceuticals, Inc. (Nasdaq:...
UBS Group AG (NYSE:UBS) – UBS reported a net profit of $1.136 billion in Q2, exceeding the $528 million forecast. Revenue also surpassed expectations, reaching $11.904 billion. Despite...
โ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 โ โ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 โ โ Raising 2024 Full...
Delivers more โGood Onโ time with less frequent dosing compared to Immediate Release CD/LD Underscores Amnealโs leadership in Parkinsonโs disease and commitment to one million people currently...
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year โ will launch in third quarter Amneal Pharmaceuticals...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions